Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sailaja Bhaskar"'
Publikováno v:
BMC Oral Health, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Healthcare professionals, especially dentists and dental hygienists, are at increased risk for contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through air-borne particles and splatter. This study assessed
Externí odkaz:
https://doaj.org/article/89c4ff728896451099f5702387a828e4
Publikováno v:
Infectious Diseases and Therapy
Introduction Polyvinylpyrrolidone–iodine (PVP-I) demonstrates broad-spectrum anti-infective activity and is available in different formulations for oral rinse and topical use in medical and personal care settings. The novel severe acute respiratory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b467062998e43dbc01f89ad28c8c230
http://europepmc.org/articles/PMC8477977
http://europepmc.org/articles/PMC8477977
Autor:
Marc Cataldo, Graeme Donnelly, Andrew J. Cutler, Ann Childress, Jaromir Mikl, Sailaja Bhaskar, James Waxmonsky
Publikováno v:
Journal of attention disorders. 26(14)
Objective: To compare the effect of a once-daily extended-release methylphenidate formulation (PRC-063) versus placebo on sleep, measured via daily electronic diary in two clinical trials in pediatric (6–12 years) and adult (≥18 years) patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de4f4b678ff2ca0bd02b9995cf8fddc0
https://pubmed.ncbi.nlm.nih.gov/35786058
https://pubmed.ncbi.nlm.nih.gov/35786058
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objective: To determine the safety and efficacy of PRC-063, a once-daily, multilayer, extended-release (ER) formulation of methylphenidate (MPH) hydrochloride, in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children in a rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4fb3f6c6b7d4f84b03277ab54ec2a6b
http://europepmc.org/articles/PMC7757528
http://europepmc.org/articles/PMC7757528
Publikováno v:
Journal of attention disorders. 26(6)
Objective: To evaluate the efficacy, safety, and duration of action of the once-daily extended-release methylphenidate formulation PRC-063 for the treatment of ADHD in an adult laboratory classroom (ALC). Method: After dose optimization with PRC-063
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eca3a42170bc6bc14d961f41be2bb12
https://pubmed.ncbi.nlm.nih.gov/34189995
https://pubmed.ncbi.nlm.nih.gov/34189995
Autor:
Hana Mekonnen, Kazem Kazempour, Hadine Joffe, Joel Lippman, JoAnn V. Pinkerton, Sailaja Bhaskar
Publikováno v:
Menopause (New York, N.y.)
Objective Sleep disturbances are common among women in midlife; prevalence increases among perimenopausal/postmenopausal women with vasomotor symptoms. Paroxetine 7.5 mg is the only nonhormonal treatment that has been approved in the United States fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be88246913b67569dc2aca7a201fc1a4
https://doi.org/10.1097/gme.0000000000000311
https://doi.org/10.1097/gme.0000000000000311
Autor:
Sailaja Bhaskar, Kazem Kazempour, Joel Lippman, Hana Mekonnen, David Portman, Andrew M. Kaunitz
Publikováno v:
Menopause (New York, N.y.)
Supplemental digital content is available in the text.
Objective Two phase 3, randomized, placebo-controlled trials demonstrated that low-dose paroxetine 7.5 mg reduced the frequency and severity of vasomotor symptoms (VMS) associated with menop
Objective Two phase 3, randomized, placebo-controlled trials demonstrated that low-dose paroxetine 7.5 mg reduced the frequency and severity of vasomotor symptoms (VMS) associated with menop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a5c7a17eb20f56424122023d300ea26
https://doi.org/10.1097/gme.0000000000000210
https://doi.org/10.1097/gme.0000000000000210
Autor:
Hana Mekonnen, David Portman, Sailaja Bhaskar, Kazem Kazempour, James A. Simon, Andrew M. Kaunitz, Joel Lippman
Publikováno v:
Menopause (New York, N.Y.). 20(10)
The efficacy and safety of low-dose paroxetine 7.5 mg for the treatment of menopausal vasomotor symptoms were evaluated in two multicenter, double-blind, placebo-controlled, phase 3 studies of 12 and 24 weeks' duration.Postmenopausal women were rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d603429cbcd5277bd0c48561a64a8b4b
https://pubmed.ncbi.nlm.nih.gov/24045678
https://pubmed.ncbi.nlm.nih.gov/24045678
Publikováno v:
Clinical therapeutics. 35(6)
Background Low-dose mesylate salt of paroxetine (LDMP 7.5 mg) is being investigated for the treatment of vasomotor symptoms associated with menopause. Objective This Phase I, open-label, single- and multiple-dose study evaluated the pharmacokinetic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d060c80bb99affdb511588cb0bd10fc5
https://pubmed.ncbi.nlm.nih.gov/23795577
https://pubmed.ncbi.nlm.nih.gov/23795577
Autor:
James A. Simon, Joel Lippman, Sailaja Bhaskar, David Portman, Hanna Mekonnen, Kazem Kazempour
Publikováno v:
Obstetrics & Gynecology. 123:132S-133S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb4bbbf294a040a67b559fd094877684
https://doi.org/10.1097/01.aog.0000447102.46167.7b
https://doi.org/10.1097/01.aog.0000447102.46167.7b